Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. (Q45937919)

18 December 2017

review article

1 reference

title

Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents. (English)

1 reference

18 December 2017

1 reference

1 reference

D C Calverley

1

1 reference

18 December 2017

G J Roth

series ordinal

2

1 reference

18 December 2017

publication date

1 December 1998

1 reference

18 December 2017

Hematology / Oncology Clinics of North America

published in

1 reference

18 December 2017

volume

12

1 reference

18 December 2017

issue

6

1 reference

18 December 2017

page(s)

1231-49, vi

1 reference

18 December 2017

Atrial fibrillation and stroke. Three new studies, three remaining questions

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Protein kinase C, calcium and phospholipid degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Drugs and surgery in the prevention of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Inhibition of platelet prostaglandin synthetase by oral aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

A Platelet-Inhibitor-Drug Trial in Coronary-Artery Bypass Operations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Low-dose aspirin and stroke. "It ain't necessarily so"

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Ticlopidine in unstable angina. A more expensive aspirin?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Does 111indium-platelet deposition predict patency in prosthetic arterial grafts?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Atrial fibrillation and stroke. Revisiting the dilemmas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Prevention of Thrombosis in Patients on Hemodialysis by Low-Dose Aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

An Overview of the British and American Aspirin Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Recovery of Endothelial Cell Prostacyclin Production after Inhibition by Low Doses of Aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Phospholipid precursors of prostaglandins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Clinical pharmacokinetics of salicylates: a re-assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Inositol phosphate biochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Influence of aspirin and dipyridamole on patency of coronary artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Antiplatelet rather than anticoagulant therapy with coronary stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Clinical implications of prostaglandin and thromboxane A2 formation (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Aspirin as an antiplatelet drug

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Clinical pharmacology of platelet cyclooxygenase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Estimated rate of thromboxane secretion into the circulation of normal humans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Acetylation of prostaglandin synthase by aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Absorption kinetics of aspirin in man following oral administration of an aqueous solution

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

1 reference

7 January 2021

Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Antithrombotic therapy for cerebrovascular disorders. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Photolabeling of Prostaglandin Endoperoxide H Synthase-1 with 3-Trifluoro-3-(m-Iiodophenyl)diazirine as a Probe of Membrane Association and the Cyclooxygenase Active Site

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Final report on the aspirin component of the ongoing Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Aspirin, heparin, or both to treat acute unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

The effect of salicylates on the hemostatic properties of platelets in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970051-4

7 January 2021

10.1016/S0889-8588(05)70051-4

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017